全文获取类型
收费全文 | 5071篇 |
免费 | 289篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 57篇 |
妇产科学 | 102篇 |
基础医学 | 602篇 |
口腔科学 | 53篇 |
临床医学 | 441篇 |
内科学 | 1657篇 |
皮肤病学 | 125篇 |
神经病学 | 543篇 |
特种医学 | 84篇 |
外科学 | 554篇 |
综合类 | 8篇 |
一般理论 | 4篇 |
预防医学 | 462篇 |
眼科学 | 31篇 |
药学 | 240篇 |
中国医学 | 5篇 |
肿瘤学 | 401篇 |
出版年
2024年 | 2篇 |
2023年 | 23篇 |
2022年 | 60篇 |
2021年 | 138篇 |
2020年 | 69篇 |
2019年 | 138篇 |
2018年 | 174篇 |
2017年 | 103篇 |
2016年 | 99篇 |
2015年 | 111篇 |
2014年 | 207篇 |
2013年 | 322篇 |
2012年 | 497篇 |
2011年 | 415篇 |
2010年 | 263篇 |
2009年 | 237篇 |
2008年 | 363篇 |
2007年 | 435篇 |
2006年 | 362篇 |
2005年 | 333篇 |
2004年 | 292篇 |
2003年 | 244篇 |
2002年 | 206篇 |
2001年 | 26篇 |
2000年 | 17篇 |
1999年 | 24篇 |
1998年 | 41篇 |
1997年 | 39篇 |
1996年 | 27篇 |
1995年 | 28篇 |
1994年 | 23篇 |
1993年 | 19篇 |
1992年 | 7篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 1篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1953年 | 1篇 |
1948年 | 1篇 |
排序方式: 共有5385条查询结果,搜索用时 15 毫秒
41.
42.
43.
44.
45.
Ximena Terra PhD Teresa Auguet MD PhD Zaida Agüera MSc Isabel Maria Quesada Josep Maria Orellana‐Gavaldà PhD Carmen Aguilar PhD Susana Jiménez‐Murcia PhD Alba Berlanga MSc Esther Guiu‐Jurado MSc José Manuel Menchón MD Fernando Fernández‐Aranda PhD Cristóbal Richart MD PhD 《The International journal of eating disorders》2013,46(8):855-861
46.
47.
48.
49.
Dafina Petrova Marina Polln Miguel Rodriguez-Barranco Dunia Garrido Josep M. Borrs Maria-Jos Snchez 《British journal of cancer》2021,124(12):2017
Background The patient interval—the time patients wait before consulting their physician after noticing cancer symptoms—contributes to diagnostic delays. We compared anticipated help-seeking times for cancer symptoms and perceived barriers to help-seeking before and after the coronavirus pandemic.Methods Two waves (pre-Coronavirus: February 2020, N = 3269; and post-Coronavirus: August 2020, N = 1500) of the Spanish Onco-barometer population survey were compared. The international ABC instrument was administered. Pre–post comparisons were performed using multiple logistic and Poisson regression models.Results There was a consistent and significant increase in anticipated times to help-seeking for 12 of 13 cancer symptoms, with the largest increases for breast changes (OR = 1.54, 95% CI 1.22–1–96) and unexplained bleeding (OR = 1.50, 1.26–1.79). Respondents were more likely to report barriers to help-seeking in the post wave, most notably worry about what the doctor may find (OR = 1.58, 1.35–1.84) and worry about wasting the doctor’s time (OR = 1.48, 1.25–1.74). Women and older individuals were the most affected.Conclusions Participants reported longer waiting times to help-seeking for cancer symptoms after the pandemic. There is an urgent need for public interventions encouraging people to consult their physicians with symptoms suggestive of cancer and counteracting the main barriers perceived during the pandemic situation.Subject terms: Cancer epidemiology, Cancer screening, Signs and symptoms, Public health, Diagnosis 相似文献
50.
Andrew X. Zhu Richard S. Finn Yoon-Koo Kang Chia-Jui Yen Peter R. Galle Josep M. Llovet Eric Assenat Giovanni Brandi Kenta Motomura Izumi Ohno Bruno Daniele Arndt Vogel Tatsuya Yamashita Chih-Hung Hsu Guido Gerken John Bilbruck Yanzhi Hsu Kun Liang Ryan C. Widau Chunxiao Wang Paolo Abada Masatoshi Kudo 《British journal of cancer》2021,124(8):1388
Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2).Methods Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed.Results Baseline AFP was confirmed as a continuous (REACH, REACH-2; p < 0.0001) and dichotomous (≥400 vs. <400 ng/ml; REACH, p < 0.01) prognostic factor, and was predictive for ramucirumab survival benefit in REACH (p = 0.0042 continuous; p < 0.0001 dichotomous). Time to AFP (hazard ratio [HR] 0.513; p < 0.0001) and radiographic (HR 0.549; p < 0.0001) progression favoured ramucirumab. Association between AFP and radiographic progression was shown for up to 6 (odds ratio [OR] 5.1; p < 0.0001) and 6–12 weeks (OR 1.8; p = 0.0065). AFP response was higher with ramucirumab vs. placebo (p < 0.0001). Survival was longer in patients with an AFP response than patients without (13.6 vs. 5.6 months, HR 0.451; 95% confidence interval, 0.354–0.574; p < 0.0001).Conclusions AFP is an important prognostic factor and a predictive biomarker for ramucirumab survival benefit. AFP ≥ 400 ng/ml is an appropriate selection criterion for ramucirumab.Clinical Trial Registration ClinicalTrials.gov, REACH () and REACH-2 ( NCT01140347).Subject terms: NCT02435433Oncology, Biomarkers 相似文献